|
TAF9 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.82409976012821E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.15789949745238E-10 |
| Normal-vs-Stage2 |
4.448600E-04 |
| Normal-vs-Stage3 |
7.64130000385776E-08 |
| Normal-vs-Stage4 |
1.78970005482171E-09 |
| Stage1-vs-Stage2 |
5.407400E-01 |
| Stage1-vs-Stage3 |
8.006600E-01 |
| Stage1-vs-Stage4 |
1.316560E-01 |
| Stage2-vs-Stage3 |
4.564800E-01 |
| Stage2-vs-Stage4 |
1.225030E-01 |
| Stage3-vs-Stage4 |
2.264400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.76120246059486E-11 |
| Normal-vs-AfricanAmerican |
6.161400E-04 |
| Normal-vs-Asian |
2.03249999997102E-06 |
| Caucasian-vs-AfricanAmerican |
6.393600E-01 |
| Caucasian-vs-Asian |
6.839400E-01 |
| AfricanAmerican-vs-Asian |
8.860200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.10959999364024E-09 |
| Normal-vs-Female |
9.43589983926074E-10 |
| Male-vs-Female |
3.108000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.00259997473751E-09 |
| Normal-vs-Age(41-60Yrs) |
5.51250001201709E-09 |
| Normal-vs-Age(61-80Yrs) |
4.79139999898237E-08 |
| Normal-vs-Age(81-100Yrs) |
1.033390E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.539200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.966000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.127800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.077600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.924600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.073200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.521400E-01 |
| Classical-VS-Follicular |
2.101400E-01 |
| Classical-VS-Other |
5.667400E-01 |
| Classical-VS-Normal |
1.4381051904877E-11 |
| Tall-VS-Follicular |
3.692800E-01 |
| Tall-VS-Other |
6.363400E-01 |
| Tall-VS-Normal |
3.92359999999981E-05 |
| Follicular-VS-Other |
4.382000E-01 |
| Follicular-VS-Normal |
1.799180E-04 |
| Other-VS-Normal |
3.543400E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.94630000396978E-08 |
| Normal-vs-N1 |
2.51080000124304E-08 |
| N0-vs-N1 |
3.444600E-01 |
|
|
